Vaccine (Peptide vaccine) · Immune activation · developed by Immatics Biotechnologies GmbH
IMA910 is a synthetic peptide vaccine containing 13 tumor-associated peptides (TUMAPs), each representing a tumor-associated antigen specific for colorectal cancer. It is designed to elicit a cytotoxic T-lymphocyte response against colorectal tumors expressing these antigens. It is studied in colorectal carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00785122 | Phase 1/2 | Colorectal Carcinoma | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →